AstraZeneca Pharmaceuticals and Bristol-Myers Squibb were hit with 14 suits in the District of New Jersey on Tuesday claiming that users of diabetes drug saxagliptin face elevated risks of heart failure as a result of using the drug.
According to the plaintiffs, the defendants failed to warn users that the drug—sold under the names Onglyza and Kombiglyze XR—can cause cardiac arrest, congestive heart failure and death.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
